Kazakhstan faces a rising burden of cancer cases that places steady pressure on its healthcare system to secure consistent, high-quality oncology medicines. Domestic production capacity remains limited for many complex therapies, creating dependence on imports. At the same time, India has emerged as a global hub for pharmaceutical manufacturing, particularly for oncology products. A well-equipped